Scientific summary
Background Interferon gamma release assays (IGRAs) are blood tests recommended for diagnosis of tuberculosis (TB) infection. The two types of commercially available IGRAs are QuantiFERON GOLD In-Tube (QFT-GIT; Cellestis, Carnegie, VIC, Australia), a whole-blood enzyme-linked immunosorbent assay (ELISA), and T-SPOT.TB ® (Oxford Immunotec, Abingdon, UK), an enzyme-linked immunospot assay (ELISpot). There is currently uncertainty in the role and clinical utility of IGRAs in the diagnostic workup of suspected active TB in routine NHS clinical practice.
Aim
To evaluate and compare the diagnostic accuracy and cost-effectiveness of IGRAs for the diagnosis of active TB.
Objectives
Primary objectives l To compare the diagnostic performance [sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)] of T-SPOT.TB and QFT-GIT for the diagnosis of active pulmonary and extrapulmonary TB in routine clinical practice. l To develop an evidence-based optimal testing algorithm that defines the role of IGRAs in the diagnostic workup of suspected active TB. l To deliver the above objectives for a key subgroup: human immunodeficiency virus (HIV) co-infected patients (the highest-risk subgroup of TB). l To quantify and compare the cost-effectiveness of a range of possible testing strategies against the present testing regime.
Secondary objectives
l To quantify the sensitivity, specificity, and PPV and NPV of T-SPOT.TB and QFT-GIT in a number of key patient subgroups, such as patients with pre-existing diabetes mellitus, end-stage renal failure and iatrogenic immunosuppression. l To quantify the use of second-generation IGRAs compared with existing commercially available assays.
Methods
We used a within-patient (paired) design to compare test accuracy by applying all IGRAs to blood samples from each patient. The final diagnosis of participants was verified using a composite reference standard (based on the Dosanjh's criteria) applied by a panel of clinicians blinded to local (routine) and study IGRA results. The diagnostic accuracy of early secretory antigenic 6 kDa (ESAT-6) and culture filtrate protein 10 (CFP-10) (together these antigens constitute T-SPOT.TB) and four new ELISpot-based assays utilising novel Mycobacterium tuberculosis antigens (Rv3615c, Rv2654, Rv3879c and Rv3873) were also evaluated, both individually and in test combinations. The test combinations were compared with T-SPOT.TB.
Statistical analysis
The main clinical utility of IGRAs in the assessment of suspected active TB is likely to be in their NPV, which enables clinicians to reliably rule out TB from the differential diagnoses. This depends on the sensitivity of the test and the prevalence of active TB in the tested population. To detect a 10% difference in sensitivity between T-SPOT.TB and QFT-GIT (assuming a sensitivity of 85% for T-SPOT.TB and of 75% for QFT-GIT) at the 5% significance level with 90% power, 855 participants were required, assuming a 40% prevalence of active TB. To allow for missing data, indeterminate index test and reference standard results, withdrawal of consent and possible logistical errors, we aimed to recruit 1012 patients. For the HIV-positive subgroup, we computed sample size based on sensitivities of 85% and 65% for T-SPOT.TB and QFT-GIT, respectively. We assumed a 20% prevalence of active TB and so required 390 participants to detect a 20% difference with 80% power.
We estimated sensitivity, specificity, PPV and NPV and likelihood ratios for each test and combinations of tests. For test comparisons, relative test performance was assessed by comparing the sensitivity and specificity of one test relative to those of another test. The comparisons between different IGRAs were done using generalised estimating equation models to exploit the paired nature of the data. Variation in the relative performance of T-SPOT.TB and QFT-GIT with HIV infection status and other clinical characteristics was investigated by including one covariate at a time in the models.
Economic evaluation
The economic analyses were based on the main study cohort. The diagnostic tests performed, their costs, and time taken between decision points involving each test were considered in the economic analyses. The analysis was undertaken from a NHS perspective. No discounting was required, as the diagnostic process occurs over a relatively short time period. For preference estimates we followed the National Institute for Health and Care Excellence (NICE) reference case, using quality-of-life weights obtained from the literature. A decision tree model was developed to calculate the incremental costs and incremental health utilities [quality-adjusted life-years (QALYs)] of changing from current practice to using an IGRA as an initial rule-out test. The model was parameterised using the IGRAs for Diagnostic Evaluation of Active tuberculosis (IDEA) study clinical patient records and relevant current literature.
Results
Between 25 November 2011 and 31 August 2013, the IDEA study recruited 1074 adults (aged ≥ 16 years) presenting as inpatients or outpatients at 10 NHS hospital trusts in London, Slough, Oxford, Leicester and Birmingham with suspected active TB. We refer to this group as the main study cohort. Owing to low recruitment of HIV-positive patients, the study was extended to 31 December 2014 to recruit only this group of patients. Two additional hospital trusts were added. A total of 263 HIV-positive patients were recruited from 12 NHS trusts between 25 November 2011 and 19 December 2014. This is the HIV-positive substudy cohort.
In the main cohort, the median age of the 845 patients included in the analyses was 38 (range 16-86) years. Most (59.3%) were male, approximately half (48.2%) were of Indian ethnicity and 135 (16.0%) were HIV positive. There were 88 (10.4%) patients with pre-existing diabetes mellitus, 12 (1.4%) patients with chronic/ end-stage renal failure and 105 (12.3%) patients who were on immunosuppressive therapy. In the HIV-positive substudy cohort, the median age of the 201 patients included in the analyses was 43 (range 18-79) years. The majority (67.7%) were male and a substantial number were of black (45.3%) or white (37.8%) ethnicity.
Principal findings of diagnostic accuracy in main study cohort
A total of 363 (43.0%) patients had a diagnosis of active TB (culture-confirmed and highly probable TB cases), whereas active TB was excluded in 439 (52.0%) patients. The remaining 43 (5.1%) patients had an indeterminate final diagnosis and were excluded from all analyses of diagnostic accuracy. The rate of indeterminate IGRA results was higher for QFT-GIT (9.6%) than for T-SPOT.TB (7.0%). Indeterminate IGRA SCIENTIFIC SUMMARY: INTERFERON-GAMMA RELEASE ASSAYS FOR DIAGNOSING ACTIVE TUBERCULOSIS NIHR Journals Library www.journalslibrary.nihr.ac.uk results were excluded from the main analyses. Comparing the two IGRAs, sensitivities were 82.3% [95% confidence interval (CI) 77.7% to 85.9%] and 67.3% (95% CI 62.1% to 72.2%), whereas specificities were 82.6% (95% CI 78.6% to 86.1%) and 80.4% (95% CI 76.1% to 84.1%) for T-SPOT.TB and QFT-GIT, respectively. The sensitivity of T-SPOT.TB was superior to that of QFT-GIT [relative sensitivity 1.22, 95% CI 1.14 to 1.3; p < 0.001), but there was no statistical evidence of a difference in specificity [relative specificity 1.02, 95% CI 0.97 to 1.08; p = 0.3]. In sensitivity analyses with indeterminates included as test positives (because only a negative result can rule out TB), conclusions about differences in the sensitivities and specificities of T-SPOT.TB and QFT-GIT were unchanged.
The sensitivities of T-SPOT.TB and QFT-GIT were lower in patients with HIV co-infection than in the HIV-negative subgroup. Similarly, the two IGRAs had lower sensitivities in patients with diabetes mellitus than in patients without diabetes mellitus. Specificity was higher in HIV-positive patients than in HIV-negative patients, but was lower in patients with diabetes mellitus than in those without diabetes mellitus. Although there appeared to be differences in test performance between subgroups, there was no statistical evidence of an effect of HIV infection status or diabetes mellitus on relative test performance. The findings from these analyses should be taken with caution, as the number of test results in some subgroups was small. Because data were few, subgroup analyses were not possible for the other two key subgroups: those patients with end-stage renal failure and those on immune suppressants.
The most promising novel antigen was RV3615c, with a sensitivity that was higher than that of the other antigens. Test combinations including Rv3615c showed higher sensitivity than T-SPOT.TB. The added value of Rv3615c to T-SPOT.TB was a 9% (95% CI 5% to 12%) relative increase in sensitivity at the expense of specificity, which showed a relative decrease of 7% (95% CI 4% to 10%). The combination of CFP-10 with Rv3615c (i.e. akin to replacing ESAT-6 in T-SPOT.TB) showed a relative increase of 7% (95% CI 3% to 11%) in sensitivity and a relative decrease of 5% (95% CI 2% to 8%) in specificity.
Principal findings of diagnostic accuracy in the HIV-positive substudy cohort
A total of 32 (15.9%) patients had a diagnosis of active TB (culture-confirmed and highly probable TB cases), whereas active TB was excluded in 165 (82.1%) patients. The remaining four (2.0%) patients had an indeterminate final diagnosis and were excluded from all analyses. The indeterminate rate was 19.5% for QFT-GIT and 23.1% for T-SPOT.TB. The difference of 3.6% (95% CI -4.5% to 11.6%) was not significant (p = 0.4). Excluding indeterminate IGRA results, the sensitivities for T-SPOT.TB and QFT-GIT were 62.8% (95% CI 44.1% to 78.3%) and 56.1% (95% CI 38.3% to 72.4%), respectively, and the specificities were 83.4% (95% CI 75.7% to 88.9%) and 91.7% (95% CI 85.4% to 95.4%), respectively. The sensitivity of T-SPOT.TB was higher than that of QFT-GIT, with a relative sensitivity of 1.12 (95% CI 0.87 to 1.44). There was no statistical evidence of a difference (p = 0.4). In contrast, the specificity of T-SPOT.TB was significantly lower (p = 0.02) than that of QFT-GIT with a relative specificity of 0.91 (95% CI 0.84 to 0.99).
When indeterminate IGRA results were included in a sensitivity analysis, there was a small increase in the sensitivity of QFT-GIT but a large increase in the sensitivity of T-SPOT.TB owing to the higher indeterminate rate for T-SPOT.TB (18.2%) among active TB cases than that of QFT-GIT (5.9%). Nevertheless, there was no statistical evidence of a difference in sensitivity (p = 0.1) or specificity (p = 0.1).
Main findings of economic evaluation
Tuberculosis diagnosis rarely followed the idealised diagnostic pathways and there was considerable individual-level variability. This implies that costs of and time delays in diagnosis may be very different from typical assumptions made in economic analyses. The number and order of diagnostic tests that were performed varied between patients, as well as between final diagnosis categories. For instance, nearly all active TB patients were given a culture test and sputum spear microscopy, whereas approximately 20% and 25% of non-active TB patients were given a culture test and sputum spear microscopy, respectively. The median cost of diagnosis was highest for unconfirmed diagnosis patients (£502) followed by the non-culture-confirmed active TB patients (£476).
The use of current IGRA tests for ruling out active TB would be unlikely to be considered cost-effective if a QALY was to be valued at £20,000 or £30,000. T-SPOT.TB performed better than QFT-GIT in the cost-effectiveness analysis. The probability of being cost-effective for a willingness to pay of £20,000/QALY was 26% and 21% for T-SPOT.TB when patients with indeterminate test results were excluded or included, respectively. In comparison, the QFT-GIT probabilities were 8% and 6%, respectively.
For the study cohort, the cost saving in these scenarios ranged from £65,120 to £86,850, but the health detriment in QALYs was between -6.50 and -3.58.
Stratifying the main study cohort by HIV infection status, the HIV-negative group of patients had results similar to those from the analyses of the entire cohort. However, cost-effectiveness results were worse for the HIV-positive group, with the probability of being cost-effective at a willingness to pay of £20,000/ QALY of approximately 12% and 9% for T-SPOT.TB and QFT-GIT, respectively, when patients with indeterminate IGRA results were excluded. When patients with indeterminate IGRA results were included, the probability was 4% for both IGRAs. The HIV-positive group had ranges of cost savings and health detriment of £42,110 to £106,090 and -7.86 to -5.91, respectively.
Although IGRAs are cost saving, the health detriment is large because of delay in diagnosing active TB leading to prolonged illness. Whether there is a net health detriment or gain for the patient cohort as a whole depends on the prevalence of active TB, the performance characteristics of the rule-out test and the length of delay introduced by adding the initial rule-out test.
Conclusions

Implications for health care
Despite the significantly higher sensitivity of T-SPOT.TB over QFT-GIT, neither IGRA can be used routinely as a reliable rule-out test for suspected active TB in this patient population in secondary care. Neither IGRA was cost-effective in this setting. However, in patients in whom there is suspicion of TB, but the pre-test probability is low, the NPV of a negative T-SPOT.TB result would be correspondingly higher. Hence, it would not be unreasonable to use a negative T-SPOT.TB result to weigh the odds in favour of excluding TB from the differential diagnosis as long as the test result is interpreted with an awareness of the limited sensitivity as shown by this study.
The incorporation of novel antigens into T-SPOT.TB, in particular Rv3615c, provided high diagnostic sensitivity values coupled with a modest reduction in specificity. Notably, replacing ESAT-6 with Rv3615c also conferred higher sensitivity than T-SPOT.TB. This observation is relevant for TB control internationally because one of the leading TB vaccine candidates in clinical trials, H56/IC31 [Statens Serum Institute, Copenhagen, Denmark; Aeras, Rockville, MD, USA; formulated with Valneva's IC31 ® proprietary adjuvant (Lyon, France)] incorporates ESAT-6. The vaccine is protective in the non-human primate model and is likely to be licensed if it proves to be protective in humans. If rolled out, vaccinated individuals are likely to develop T-cell responses to ESAT-6 that would lead to false-positive IGRA results, akin to the current scenario with bacillus Calmette-Guérin (BCG) vaccination inducing false-positive tuberculin skin test results. Replacing ESAT-6 with Rv3615c may be a potential solution because a CFP-10-and Rv3615c-based IGRA would have significantly higher sensitivity than existing IGRAs and specificity would not be compromised in H56/IC31vaccinated individuals.
Recommendations for research
The second-generation IGRAs evaluated in the IDEA study do not need to be re-evaluated in a UK routine practice setting because this study provided an equally rigorous evaluation of these novel assays, as it did for conventional IGRAs. However, the novel assays require evaluation in distinct clinical settings with much lower or much higher prevalence of active TB and in immunosuppressed subgroups. A new generation of QFT-GIT, QuantiFERON-TB Gold Plus (QFT ® -Plus; Qiagen GmbH, Hilden, Germany), was recently launched.
